NorthWest Biotherapeutics Inc (NWBO)

[Evaluate]

UCLA owns DCVax L, really. NWBO licenses it from them. NWBO have some of their own patents on manufacturing, including automation, but whatever collaborations UCLA enters into with BP will not benefit NWBO. --- Pyrr

Tricky question.
Some clues in this Exhibit 10.35 between UCLA & NWBO in 2006?
https://agreements.wordpress.com/2008/05/03/ucla-clinical-study-agreement-from-realdealdocscom/
One such clue might be:

F. The Investigator shall limit the use and evaluation of Study Drug, as defined herein, to activities directly related to the Protocol and shall not transfer any Company Study Drug to any third party, without the prior written consent of Company.

but:

3. TERM: This Agreement shall become effective as of the last date of signing by the last party to sign and shall continue until completion of the Study or until termination pursuant to Article 13.

... so perhaps this only related to Phase I .... and ended upon completion of Phase I ... perhaps there is subsequent agreement in place?
Seems to me that NWBO has reported that they have hundreds of patents in place related to DCVax .... in many different countries (beyond USA & Europe ... ie also in Japan or China?). These patents seem to go far beyond just the manufacturing and automation aspects.
You seem convinced UCLA owns DCVax-l ... based on what?

You also wrote:

Are you arguing BCG is used in DCVax L? Of course it's not. --- Pyrr

From slide 29 it appears that BCG actually IS used in DCVax: http://www.nwbio.com/NWBT_corp_overview_(Biotech_Showcase_updated)_1-12-15.pdf

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3999913/
includes:

Liau et al demonstrated that autologous DC incubated with autologous tumor protein increased survival, and increased tumor-specific cytotoxic T cells within the tumor [9]. These initial studies that were performed in only a few patients led to clinical trials. Different methods to activate these DC were explored. Expanding the immune response was first approached by using non-specific immunomodulators, such as BCG, IL-2, interferon (IFN)-a, which had been registered as approved immunostimulants.